Provided is a pre-filled drug package that can inhibit protein aggregation after long-term storage even when accommodating a protein solution formulation having a low non-ionic surfactant concentration. The pre-filled drug package includes a protein solution formulation and a housing accommodating the protein solution formulation. The protein solution formulation has a non-ionic surfactant concentration of not less than 0 mg/mL and less than 0.05 mg/mL. At least part of a section of the housing that is in contact with the protein solution formulation is formed of a resin including either or both of a hydrogenated cycloolefin ring-opened polymer and a copolymer of a cycloolefin and a chain olefin.

An aseptic closure system for attaching to a container including an upper section and a lower section that are removably attached to one another. Each section includes a valve housing with a rotary valve mounted in a bore extending through the valve housing. The upper section has an inlet port and an outlet port, each with a conduit providing fluid communication through the port to an interior of the upper valve housing. The lower section is adapted to mount to a container. The lower valve housing includes two conduits that permit fluid communication through the lower valve housing to an interior of the lower section. The rotation of the rotary valves closes off flow through the conduits in the respective housings.

A secure specimen sample bottle includes a base container for receiving a specimen. The base container has a plurality of locking protrusions formed along an inner surface of the base receptacle. A bottle includes a lock ring that has an upright spire structure that has a closed top end and the opposing open bottom end including a plurality of flexible fins that are configured to interlockingly mate with the locking protrusions so as to prevent removal of the lock ring relative to the base container upon engagement of the flexible fins to the locking protrusions. A removable cap is coupled to the lock ring.

A sealed pharmaceutical container includes a shoulder, a neck extending from the shoulder, and a flange extending from the neck. The flange includes an inclined sealing surface defining an opening in the sealed pharmaceutical container. The sealed pharmaceutical container also includes a sealing assembly including a stopper extending over the sealing surface of the flange and a cap securing the stopper to the flange. The stopper has a glass transition temperature (T.sub.g) that is greater than or equal to −70° C. and less than or equal to −45° C. The sealing assembly maintains a helium leakage rate of the sealed pharmaceutical container of less than or equal to 1.4×10.sup.−6 cm.sup.3/s as the sealed pharmaceutical container is cooled to a temperature of less than or equal to −45° C.

A sterile solution product bag includes sterilization grade filter integrated directly into the product bag such that microbial and particulate matter filtration can be performed using the filter directly at the point of fill. The filter can include a hollow fiber filter membrane contained in a stem connected to a bladder of the product bag.

The invention according to the present document discloses a device 1 configured for conveying a toxic aerosol from a drug contained in a syringe (S) or in a vial (F) toward a suction pipe, comprising a cylindrical hollow element comprising an inner space configured for accommodating a syringe so that the inner walls of said space slidingly adhere to the outer walls of the syringe barrel, provided with a proximal end 2.10 which includes an opening 2.6 configured in such a way as to allow the insertion of a syringe barrel, and a flange configured for accommodating a syringe flange, and a distal end 2.11 which includes an opening 2.7 configured in such a way as to allow the cone, fitting, and needle of said syringe to pass through, and a cap configured for being connected to said cylindrical hollow element present in two configurations, one suitable for administering a drug and another suitable for taking a drug from a vial, in particular a drug potentially releasing a toxic aerosol.

The document also discloses a method for using the kit and the device according to the invention.

Described herein is an improved bottle and lid design that eliminates the need for lids on bottles that require unscrewing, snapping, or other exertion to remove and/or replace the lid.

A top for a plasma storage container includes a top body that defines the structure of the top and seals an opening of the plasma storage container. The top also includes a first opening and a vent opening extending through the top body. A septum is located at least partially within the first opening and includes an aperture therethrough. The septum allows a blunt cannula to pass through the aperture to access the interior of the plasma storage container. The top also includes a hydrophobic membrane located on underside of the top body. The membrane covers the vent opening and allows air to vent through the vent opening during plasma collection.

A lockable container for securing items or objects, the container including a first element, which may include a cylindrical member and a retainer for capturing two or more rotatable rings on the cylindrical member, and a second element, which is mateable with the first element, cooperating with the rings to close an open end of the cylindrical member of the first element.

An inside stopper is attached at a lower end portion thereof to a medical solution container body for storing a medical solution and is provided with a brush attached to an upper end portion thereof so as to apply the medical solution. The inside stopper includes a brush inserted-and-mounted hole, to which the brush is inserted and mounted, and a pressing-for-maintaining portion that is provided in a lower end portion of the brush inserted-and-mounted hole and presses a lateral periphery of the brush so as to maintain a position of the brush with respect to the inside stopper.